Educational Notice
Peptidings provides information for educational and research purposes only. The peptides discussed on this page are subjects of ongoing scientific research. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Browse by Condition
Muscle Recovery
Muscle recovery research spans several distinct mechanisms: reducing inflammation and oxidative stress following exercise, promoting satellite cell activation and myogenesis, and modulating the IGF-1 and GH signaling pathways that govern muscle protein synthesis. The compounds in this category carry widely different evidence profiles—from tissue repair peptides with limited human data to IGF-1 splice variants that have never been tested in a human clinical trial. WADA prohibition status is a particularly relevant consideration for this category, as several compounds here are prohibited in competitive sport.
Approved Drug
Clinical Trials
Pilot / Human Data
Preclinical Only
It’s Complicated
Compounds with Research Relevant to Muscle Recovery
Each compound links to its full pillar article. The most useful sections for evaluating a specific application are the Claims vs. Evidence table and the Safety, Risks, and Limitations section. Evidence tiers reflect the strongest available data for a compound overall—not necessarily for this specific application.
WADA
BPC-157: What the Research Says about This Pentadecapeptide
Gastric pentadecapeptide studied for tissue repair, tendon healing, and gut protection. Pilot human data only; WADA prohibited.
Read the research →
CJC-1295 (No DAC): What the Research Shows
Short-acting GHRH analog studied for pulsatile growth hormone stimulation and body composition. Preclinical evidence only.
Read the research →
CJC-1295 with DAC: What the Research Shows
Long-acting GHRH analog with albumin-binding extension for sustained GH elevation. Preclinical evidence only.
Read the research →
WADA
Follistatin: Myostatin Inhibition, Muscle Growth, and the Gene Therapy Gap
Glycoprotein neutralizing myostatin. AAV-follistatin gene therapy has Phase I/II human data (Mendell, Nationwide Children's). Peptide injection has zero clinical validation.
Read the research →
GHRP-2: What the Research Shows
Synthetic GHS-R1a agonist studied for growth hormone stimulation and appetite regulation. Human pharmacokinetic data available.
Read the research →
GHRP-6: What the Research Shows
GHS-R1a agonist studied for growth hormone release and appetite stimulation. Human pharmacokinetic data available.
Read the research →
Hexarelin: What the Research Shows
Potent GHS-R1a agonist studied for growth hormone secretion and cardiac function. Phase I/II human data available.
Read the research →
WADA
IGF-1 DES: The Truncated High-Potency IGF-1 Variant
Truncated IGF-1 missing first 3 amino acids. High-potency local paracrine signaling. WADA prohibited (S2). No human trials. Short half-life limits systemic exposure.
Read the research →
WADA
IGF-1 LR3: The Extended Half-Life IGF-1 Analog
Half-life-extended IGF-1 analog with Arg3 substitution reducing IGFBP binding. WADA prohibited (S2). Zero human clinical trials. Widely used in performance communities.
Read the research →
Ipamorelin: What the Research Actually Shows
Selective GHS-R1a agonist studied for GH stimulation with minimal cortisol or prolactin effect. Preclinical evidence only.
Read the research →
WADA
MGF and PEG-MGF: Mechano Growth Factor and Its Pegylated Analog
IGF-1 splice variant E-peptides targeting satellite cell activation. PEG-MGF extends half-life via pegylation. WADA prohibited (S2). No human clinical data.
Read the research →
WADA
MK-677 (Ibutamoren): What the Research Shows
Oral GHS-R1a agonist (not a peptide) studied for GH elevation and muscle preservation. Human trial data available; WADA prohibited.
Read the research →
Sermorelin: What the Research Shows
FDA-approved GHRH analog for growth hormone deficiency diagnosis and treatment. Established clinical evidence.
Read the research →
WADA
TB-500: What the Research Says about Thymosin Beta-4’s Synthetic Fragment
Synthetic Thymosin Beta-4 fragment studied for tissue repair and cell migration. Preclinical evidence only; WADA prohibited.
Read the research →
Tesamorelin (Egrifta): What the Research Shows
FDA-approved GHRH analog (Egrifta) for HIV-associated lipodystrophy. Established clinical evidence.
Read the research →
WADA
Thymosin Beta-4: What the Research Shows
Endogenous 43-amino acid actin-sequestering peptide studied for wound healing, cardiac repair (RGN-352 Phase II), and corneal regeneration (RGN-259). TB-500 is its synthetic fragment — distinct compounds.
Read the research →
Guides Relevant to This Condition
How to Reconstitute Lyophilized Peptides
Bacteriostatic water, reconstitution ratios, vial handling
Peptide Storage and Handling Best Practices
Temperature ranges, freeze-thaw cycles, reconstituted peptide shelf life
Peptide Injection Technique Guide
Subcutaneous and intramuscular injection, site rotation, safety
Research Cluster
These compounds are covered in depth in the Performance and Body Composition Peptides cluster hub.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.